- Home
- ACCS vs TELO Comparison
ACCS vs TELO Comparison
Compare ACCS & TELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- TELO
- Stock Information
- Founded
- ACCS 1988
- TELO 2021
- Country
- ACCS United States
- TELO United States
- Employees
- ACCS N/A
- TELO N/A
- Industry
- ACCS Publishing
- TELO
- Sector
- ACCS Consumer Discretionary
- TELO
- Exchange
- ACCS Nasdaq
- TELO NYSE
- Market Cap
- ACCS 44.2M
- TELO 52.4M
- IPO Year
- ACCS N/A
- TELO 2024
- Fundamental
- Price
- ACCS $12.20
- TELO $1.76
- Analyst Decision
- ACCS Strong Buy
- TELO
- Analyst Count
- ACCS 1
- TELO 0
- Target Price
- ACCS $15.00
- TELO N/A
- AVG Volume (30 Days)
- ACCS 14.6K
- TELO 9.2M
- Earning Date
- ACCS 08-11-2025
- TELO 08-12-2025
- Dividend Yield
- ACCS N/A
- TELO N/A
- EPS Growth
- ACCS N/A
- TELO N/A
- EPS
- ACCS N/A
- TELO N/A
- Revenue
- ACCS $22,961,000.00
- TELO N/A
- Revenue This Year
- ACCS $3.05
- TELO N/A
- Revenue Next Year
- ACCS $15.47
- TELO N/A
- P/E Ratio
- ACCS N/A
- TELO N/A
- Revenue Growth
- ACCS 6.92
- TELO N/A
- 52 Week Low
- ACCS $7.79
- TELO $1.12
- 52 Week High
- ACCS $13.35
- TELO $8.40
- Technical
- Relative Strength Index (RSI)
- ACCS N/A
- TELO 48.69
- Support Level
- ACCS N/A
- TELO $2.00
- Resistance Level
- ACCS N/A
- TELO $2.44
- Average True Range (ATR)
- ACCS 0.00
- TELO 0.23
- MACD
- ACCS 0.00
- TELO 0.03
- Stochastic Oscillator
- ACCS 0.00
- TELO 31.98
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About TELO TELOMIR PHARMACEUTICALS INC
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.